Please try another search
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company’s lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Name | Age | Since | Title |
---|---|---|---|
Charles B. Shoemaker | - | 2012 | Member of Infectious Disease Scientific Advisory Board |
Steven A. Shallcross | 60 | 2015 | CEO, CFO, Treasurer, Corporate Secretary & Director |
Jeffrey Jay Kraws | 57 | 2006 | Independent Non-Executive Chairman |
Thomas J. Louie | - | 2014 | Member of C Difficile Clinical Advisory Board |
Curtis Donskey | - | 2014 | Member of C Difficile Clinical Advisory Board |
Ciarán P. Kelly | - | 2014 | Member of C Difficile Clinical Advisory Board |
Richard Hodin | - | 2020 | Member of Intestinal Alkaline Phosphatase Clinical Advisory Board |
Thomas W. Dubensky | 64 | 2022 | Member of Scientific Advisory Board |
Josep Tabernero | - | 2022 | Member of Scientific Advisory Board |
Mark S. Blumenkranz | 71 | 2022 | Member of Scientific Advisory Board |
Ennio Antonio Chiocca | - | 2022 | Member of Scientific Advisory Board |
Daniel DiMaio | - | 2022 | Member of Scientific Advisory Board |
Mark H. Wilcox | - | 2014 | Chairman of C Difficile Clinical Advisory Board |
Jeffrey Alan Wolf | 60 | 2006 | Independent Director |
John Monahan | 77 | 2011 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review